STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Investing.com - Eli Lilly's full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NYSE: NVO) is under pressure from investors for more information about its ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...